Avalo TherapeuticsAVTX
Market Cap: 11.9M
About: Avalo Therapeutics Inc is a clinical stage biotechnology company focused on the treatment of immune dysregulation. The company's lead asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
Employees: 19
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
807% more capital invested
Capital invested by funds: $209K [Q4 2023] → $1.9M (+$1.69M) [Q1 2024]
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
50% more funds holding
Funds holding: 12 [Q4 2023] → 18 (+6) [Q1 2024]
10.93% more ownership
Funds ownership: 0.01% [Q4 2023] → 10.94% (+10.93%) [Q1 2024]
25% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 4
Research analyst outlook
1 Wall Street Analyst provided 1 year price forecasts over the past 6 months
1 analyst rating
Oppenheimer Leland Gershell | 203%upside $35 | Outperform Upgraded | 16 Apr 2024 |
Financial journalist opinion
Based on 3 articles about AVTX published over the past 30 days